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Abstract
Background: Down syndrome (DS) is characterized by the presence of an extra 
full or partial human chromosome 21 (Hsa21). An invaluable model to define geno-
type‐phenotype correlations in DS is the study of the extremely rare cases of partial 
(segmental) trisomy 21 (PT21), the duplication of only a delimited region of Hsa21 
associated or not to DS. A systematic retrospective reanalysis of 125 PT21 cases 
described up to 2015 allowed the creation of the most comprehensive PT21 map and 
the identification of a 34‐kb highly restricted DS critical region (HR‐DSCR) as the 
minimal region whose duplication is shared by all PT21 subjects diagnosed with DS. 
We reanalyzed at higher resolution three cases previously published and we accu-
rately searched for any new PT21 reports in order to verify whether HR‐DSCR limits 
could prospectively be confirmed and possibly refined.
Methods: Hsa21 partial duplications of three PT21 subjects were refined by adding 
array‐based comparative genomic hybridization data. Seven newly described PT21 
cases fulfilling stringent cytogenetic and clinical criteria have been incorporated into 
the PT21 integrated map.
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1 |  INTRODUCTION
In 1959 Lejeune, Gautier, and Turpin showed that human 
chromosome 21 (Hsa21) is present in an extra copy (tri-
somy 21) in the cells of subjects with Down syndrome (DS, 
OMIM #190685) (Lejeune, Gauthier, & Turpin, 1959), the 
most common constitutional form of intellectual disability 
(ID) (Gardiner et al., 2010; Menghini, Costanzo, & Vicari, 
2011; Tolksdorf & Wiedemann, 1981). Although Hsa21 has 
the smallest number of genes among the human autosomal 
chromosomes (Piovesan, Caracausi, Antonaros, Pelleri, & 
Vitale, 2016), it has been difficult to link the function of spe-
cific Hsa21 genes to distinct phenotypic features of subjects 
with DS, whose more constant manifestations are a typical 
facies (oblique eyes, flat nasal bridge) and ID, together with 
other variable signs and symptoms (Epstein, 1989; Gardiner 
et al., 2010; Hickey, Hickey, & Summar, 2012; Letourneau 
& Antonarakis, 2012; Megarbane et al., 2009; Roizen & 
Patterson, 2003; Strippoli et al., 2013).
An invaluable model for linking genotype and phenotype 
in DS is the study of the extremely rare cases of partial (seg-
mental) trisomy 21 (PT21), the duplication of only a delim-
ited segment of Hsa21 associated or not to DS. PT21 was first 
reported by Ilbery and coll. (Ilbery, Lee, & Winn, 1961) as 
"incomplete trisomy" and has been widely studied by meth-
ods with an increasing power of resolution in order to estab-
lish correlations between the gene content of the duplicated 
segment and the associated signs and symptoms (reviewed in 
(Pelleri et al., 2016)). These studies have strongly supported 
the concept that not all Hsa21 loci are required for the mani-
festation of DS, as anticipated by Lejeune who hypothesized 
the presence of a few "culprits among so many innocents" on 
Hsa21 because if most of the genes would produce harm when 
in triplicate, "trisomic children would not survive at all. Few 
of the accelerated reactions are dangerous" (Lejeune, 1990).
Following multiple case reports of individuals with PT21 
in the 70s–90s, the concept of "Down syndrome critical re-
gion" (DSCR) arose, with different grades of support from 
different authors (reviewed in (Pelleri et al. (2016)). Systematic 
attempts were then published in 2009 to identify "critical re-
gions" on Hsa21 for several distinct phenotypes observed in 
DS, exploiting the availability of a larger number of cases 
(Korbel et al., 2009; Lyle et al., 2009). We have recently pro-
posed a systematic reanalysis of all described PT21 cases 
(from 1973 to 2015) by building an integrated, comparative 
map of 125 cases with or without DS fulfilling stringent cyto-
genetic and clinical criteria (Pelleri et al., 2016). An innova-
tion was also the use of the diagnosis of DS as the phenotype 
to be mapped, thus focusing on the Hsa21 minimal duplicated 
region shared by all the subjects diagnosed with DS, whose 
most constant features are ID and some facial phenotypes, 
that is oblique eyes and flat nasal bridge. The thorough re-
analysis and comparison of the data available over several de-
cades required the correction and update of cytogenetic band 
boundaries as well as of relative order and exact position of 
many genomic markers, integration of analyses subsequently 
performed in the course of years on the same identifiable 
subjects even if reported by different authors, corrections 
of incongruencies in clinical classification or cytogenetic 
characterization, and removal of cases with any residual un-
certainty in the presentation of data. This approach finally 
allowed the inclusion or exclusion of fine Hsa21 sequence 
intervals as candidates for DS, also integrating duplication 
copy number variants (CNVs) data. The main result was 
the identification of a highly restricted DSCR (HR‐DSCR) 
of only 34 kilobases (kb) on distal 21q22.13 as the minimal 
region whose duplication is shared by all DS subjects and 
is absent in all non‐DS subjects, containing no known gene 
and with relevant homology only to the chimpanzee genome 
(Pelleri et al., 2016).
Radius S.r.l.—Technology for life (www.
radiu stech.it). Results: The PT21 map now integrates fine structure of Hsa21 sequence intervals 
of 132 subjects onto a common framework fully consistent with the presence of a 
duplicated HR‐DSCR, on distal 21q22.13 sub‐band, only in DS subjects and not in 
non‐DS individuals. No documented exception to the HR‐DSCR model was found.
Conclusions: The findings presented here further support the association of the HR‐
DSCR with the diagnosis of DS, representing an unbiased validation of the original 
model. Further studies are needed to identify and characterize genetic determinants 
presumably located in the HR‐DSCR and functionally associated to the critical mani-
festations of DS.
K E Y W O R D S
computational biology, Down syndrome, highly restricted Down syndrome critical region, human 
chromosome 21, intellectual disability, partial trisomy 21
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When a similar systematic approach has been applied to 
congenital heart disease (CHD) in subjects with DS, a more 
distal region has been shown to be associated to CHD in DS, 
possibly with different limits according to the specific type of 
CHD, in the context of a multifactorial model (Pelleri et al., 
2017). These findings further support the specificity of the 
results previously obtained for the HR‐DSCR that appears to 
be more proximal, well‐delimited, and monofactorial in its 
association to the diagnosis of DS.
Further studies are needed to confirm that HR‐DSCR is 
really functionally associated to the critical manifestations 
of DS, and in particular to ID. While research is in progress 
to identify functioning loci still unknown but possibly pres-
ent in the HR‐DSCR, it is also fundamental to continue the 
study of any new cases of PT21 and to refine the limits of 
the trisomic Hsa21 portions in cases already studied at low 
resolution. The confirmation that there is no documented 
exception to the HR‐DSCR model would further encourage 
molecular studies in this small segment of Hsa21 as well as 
high resolution analysis to investigate some very interesting 
cases reported in 90s: they are five phenocopies (people with 
DS phenotype and no evidence of cytogenetic/molecular 
alteration) (Ahlbom et al., 1996; Anneren & Edman, 1993; 
McCormick et al., 1989) and the opposite condition of appar-
ent full trisomy 21 without DS phenotype (Avramopoulos et 
al., 1997). No marker through high resolution techniques was 
analyzed within the HR‐DSCR, therefore the possibility that 
a very small Hsa21 region might be involved in the expres-
sion of basic DS features cannot be excluded.
Due to the rarity of these particular cases as well as of 
PT21 cases, an international collaborative effort would be de-
sirable in order to perform cutting‐edge analysis and collect 
new data.
In this light, the aim of this study was to reanalyze at 
higher resolution three cases already included in the PT21 
integrated map in order to verify whether this analysis could 
help in confirming and refining the limits of the HR‐DSCR. 
In addition, we accurately searched for any new reports of 
PT21 subsequent to the original study to integrate the new 
data in the existing PT21 map searching again for confirma-
tion or rejection of the original model. This second approach 
is of particular relevance because, being a prospective study 
started after the first description of HR‐DSCR, it represents 
an unbiased validation of the original model that could also 
be performed in the future.
2 |  MATERIALS AND METHODS
2.1 | Molecular cytogenetic characterization
In order to update the PT21 map (125 PT21 cases with or 
without DS) previously published (Pelleri et al., 2016), we 
reanalyzed at higher resolution three cases already included 
in the previous map. These three reanalyzed cases are num-
bered here from 1 to 3 (Table 1); the correspondence with 
previous map identifiers ("Map ID" in (Pelleri et al., 2016)) 
and with updated map identification numbers ("Map ID 
here") is reported in Table 1.
Array–based comparative genomic hybridization (array‐
CGH) analysis was performed on DNA from three patients 
by using two different Agilent Technologies platforms 
(Agilent Technologies, Santa Clara, CA), following the 
manufacturer's protocol: SurePrint G3 Unrestricted CGH 
ISCA v2, with an average resolution of 60 kb, for MP01 
and MP03 (cases 1 and 2, Table 1), and Human Genome 
CGH 60k Oligo Microarray Kit, with a median spatial res-
olution of 41.5 Kb, for proband case number 3 (Table 1). A 
graphical visualization of the results was provided by the 
Genomic Workbench software v.7.0 for the three patients 
and aberrations were called by the ADM1 algorithm with 
threshold at 6.0.
2.2 | Bibliographic searches and 
case selection
We accurately searched for any reports of PT21 to integrate 
the new data in the previous PT21 map.
Bibliographic searches performed to build the starting map 
(Pelleri et al., 2016) were repeated in order to identify newly 
reported cases of PT21. "Mirror duplication chromosome 
21" was used as additional PubMed query on the National 
Center for Biotechnology Information  (NCBI) site (https ://
www.ncbi.nlm.nih.gov/pubme d/) and references cited in turn 
in the retrieved reports were examined. In addition, a search 
for "partial trisomy 21" through Google web search engine 
(https ://www.google.com/) was performed.
Only new PT21 subjects with sufficient and unambiguous 
descriptions at the cytogenetic, molecular, and clinical levels 
were included in the study, following inclusion and exclu-
sion criteria as previously described in detail (Pelleri et al., 
2016). Briefly, the main cytogenetic inclusion criterion was 
the presence of a 21q partial duplication, excluding from the 
analysis cases presenting translocations and ring Hsa21 with 
a complete 21q, tetrasomies of Hsa21, mosaic trisomy 21, 
chromosomal rearrangements involving the X chromosome, 
and chromosomal alterations described in leukemic cell 
clones. For the molecular analysis criteria, the condition was 
a detailed and unambiguous description of the duplicated seg-
ment boundaries. At the clinical level, subjects were classi-
fied as "DS" or "non‐DS" according to the following criteria: 
(a) explicit statements found in the study; (b) whether authors 
judged recognizable DS as present or absent, irrespectively 
of other symptoms or signs associated to possibly concur-
rent aneuploidies of non‐Hsa21 chromosomal segments; (c) 
assessment of detailed phenotype description when present 
in the article.
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The cases thus retrieved were numbered starting from 4 
to 10 following chronological order of first description in 
literature.
2.3 | Case descriptions
Main clinical data of the reanalyzed or reviewed cases are 
summarized in Table 1.
Briefly, the first two reanalyzed cases were subjects 
MP01 and MP03 (cases 1 and 2, Table 1). They were 
firstly reported in 1989 (McCormick et al., 1989) and 
1990 (Petersen et al., 1990). According to the checklist of 
Jackson et al. (Jackson, North, & Thomas, 1976), a pheno-
typic score consistent with the clinical diagnosis of DS was 
reported for patient MP01, while patient MP03's pheno-
typic score is below the threshold for the clinical diagnosis 
of DS (Petersen et al., 1990).
The third reanalyzed case (case 3 in Table 1) was first 
reported in 1997 (Mattina et al., 1997) and we present clini-
cal data from the follow‐up of the patient here. The proband 
is the only child of nonconsanguineous parents, born at the 
40th week of gestation with eutocic delivery after an un-
complicated pregnancy; low‐risk triple test; birth weight was 
3,020 g. The child was admitted to hospital for the first time 
at birth due to neonatal asphyxia and dysmorphic signs. The 
traditional karyotype through fluorescence in situ hybridiza-
tion (FISH) was: 47, XX, +der21, t(9;21), but the patient was 
recognized as affected by a chromosomal syndrome due to 
a double partial trisomy 9q34.1‐>qter, 21pter‐>21q22.11. 
She was repeatedly admitted to the polyclinic due to frequent 
bronchopneumonic episodes and apnea crises. She is cur-
rently followed by annual follow‐up at the Medical Genetics 
Clinic. In agreement with the parents, clinical controls are 
carried out only within the limits of the "availability" of the 
girl. The girl shows a clinical picture with characteristics in 
agreement with partial trisomy 9q. Apparently, there are no 
clinical signs attributable to partial trisomy 21. Dysmorphic 
signs include brachycephaly, small anteverted ears with sim-
ple pavillon, straight forehead, divergent strabismus, propto-
sis, beak nose deviated to the left with narrow bridge, short 
philtrum, and "carp" mouth with thin lips. Prognathism, long 
and thin arms, hands and feet with arachnodactyly, and bi-
lateral patella dislocation were also observed. Congenital 
malformations involved the heart (ventricular sept defect), 
brain (hypoplasia of the corpus callosum and subarachnoid 
space dilation), eyes (proptosis, nystagmus, divergent stra-
bismus, pupil optic nerve pallor and hypoplasia, the patient 
underwent surgery to correct ectopia of crystalline lens and 
cataracts developed over years), skeleton (additional thoracic 
metameres with corresponding costal segments) and kidneys 
(hypoplasia‐dysplasia of the left kidney). During neonatal 
period and the first year of life, the patient did not thermo-
regulate and showed significant apnea crises, serious psychic 
and motor deficits, muscle hypotonia and hypotrophy, and 
afinalistic and uncoordinated hand movements. She pro-
nounces "mom" and "dad", does not deambulate. Menarche 
was reported in September, 2009; irregular menstrual cycle. 
She presents with hand tremor.
Descriptions of seven cases (summary in Table 1, cases 
4–10) retrieved by the new bibliographic search performed 
and mapped here have been reported in detail in the respec-
tive reports (Biaduń‐Popławska et al., 2014; Egashira et al., 
2008; Finley, Finley, Rosecrans, & Phillips, 1965; Hamm, 
Carroll, Mikhail, Korf, & Finley, 2015; Sheth et al., 2007; Su 
et al., 2016; Weisfeld‐Adams, Tkachuk, Maclean, Meeks, & 
Scott, 2016).
2.4 | Map framework building
We revised and updated all the sequence features of Hsa21 
reported to build the starting map (Pelleri et al., 2016) (here 
Table S1): known Hsa21 genes, coordinates for single nu-
cleotide polymorphisms (SNPs), sequence‐tagged sites, 
bacterial artificial chromosome clones, nucleotide posi-
tions determined by array‐CGH as limits of altered regions 
in individual subjects and cytogenetic band limits. All the 
genomic coordinates refer to the current Genome Reference 
Consortium (GRC) human genome assembly GRCh38, or 
hg38 (December 2013).
In summary, each spreadsheet row corresponds to a spe-
cific and relevant sequence feature on Hsa21 for a total of 
724 sequence intervals (rows), providing anchor points useful 
to homogeneously map each cytogenetic feature described in 
the reports of PT21.
2.5 | Comparative map building
For each subject studied, a column on the map file built as 
explained above was added, representing the structure of his/
her Hsa21. Each row represents a specific sequence inter-
val on Hsa21. Starting from the 125 PT21 cases previously 
described (Pelleri et al., 2016), we added refined limits of 
the duplicated portion for cases 1–3 to the map and mapped 
the additionally retrieved cases found with additional biblio-
graphic searches performed here (Table 1, cases 4–10).
Each row represents a specific sequence interval on Hsa21 
and for each subject with DS the corresponding cell was col-
ored following this code: red = trisomic, therefore possible 
candidate as causing DS; green = disomic, therefore excluded 
as causing DS; blue = monosomic, considered as "not dupli-
cated", therefore excluded as candidate; white = information 
not available with certainty. A complementary reasoning 
was used to color the cells representing sequence intervals 
when the subject presented cytogenetically with a segmental 
trisomy 21 in absence of a typical DS picture. In particular: 
red = disomic in non‐DS, therefore not excluded as causing 
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DS; green = trisomic in non‐DS, therefore excluded as caus-
ing DS; blue = monosomic, considered as "not duplicated", 
therefore indirectly not excluded as candidate; white  =  in-
formation not available with certainty. Headings of non‐DS 
cases are highlighted in yellow.
2.6 | Scoring system
A score was assigned to each interval sequence substantially 
following the scoring system applied by Lyle and coll. (Lyle 
et al., 2009), but attributing a lower score to not excluded 
regions in non‐DS subjects due to the fact that these regions 
would only be candidate regions indirectly.
A score of +1 was assigned to each trisomic (candidate) 
sequence interval in DS subjects, while +0.5 was assigned to 
disomic (not excluded) intervals in non‐DS subjects. A score 
of −1 was assigned to each sequence interval that was ex-
cluded as candidate for DS, being disomic in DS or trisomic 
in non‐DS subjects. Monosomic regions are considered as 
"not duplicated", therefore they should be excluded as candi-
dates in DS subjects (score = −1) and indirectly not excluded 
in non‐DS (score  =  +0.5). For each sequence interval, the 
algebraic sum of the scores is calculated, generating the final 
score for the interval. The Excel macro and the Python scripts 
implementing the described algorithms for the calculations 
of the scores and for summarizing scores along Hsa21 regular 
intervals, respectively, are available upon request.
Higher scores indicate increased probability of associa-
tion to DS. Detailed partial and final scores for each interval 
are reported in Table S1 at the right of the columns represent-
ing mapping for the 132 analyzed cases.
3 |  RESULTS
3.1 | Molecular cytogenetic characterization
The array‐CGH analysis of DNA from patient MP01 (case 
1, Map ID here #044) revealed a duplication of Hsa21 from 
36,760,100 to 46,329,175 bp (GRCh38) (Figure 1).
The array‐CGH analysis of DNA from patient MP03 (case 2, 
Map ID here #046) revealed trisomy of Hsa21 from 14,112,687 
to 28,015,203 bp (GRCh38) (Figure 2). The array did not allow 
evaluation of the Hsa21 portion upstream the proximal limit.
Regarding case 3 (Map ID here #077), duplications 
of about 13.4 megabases (Mb) in the 9q33.3‐q34.3 chro-
mosome region, of about 0.45  Mb in the 9q34.3 chromo-
some region, and of about 19  Mb in the 21q11.2‐q22.11 
chromosomal region have been highlighted. According to 
ISCN 2016 nomenclature, the alterations may be described 
as: arr[GRCh38] 9q33.3‐q34.3(123265569_136502696)
x3, 9q34.3(137666340_138059636)x3, 21q11.2‐
q22.11(13268071_32197958)x3 (Figure 3).
These new limits have been recorded in the Table S1.
3.2 | Bibliographic searches
Bibliographic searches performed to build the starting map 
(Pelleri et al., 2016) were repeated in order to identify newly 
reported cases of PT21, resulting in four newly described 
PT21 cases to be included (Table 1, cases 4 and 8–10) (Finley 
et al., 1965; Hamm et al., 2015; Su et al., 2016; Weisfeld‐
Adams et al., 2016).
Using "mirror duplication chromosome 21" as additional 
PubMed query (Pelleri et al., 2016) and examining references 
cited in turn in the retrieved reports led to the retrieval of 
two additional PT21 cases (Egashira et al., 2008; Sheth et 
al., 2007) to be included here according to selection criteria 
detailed above (Table 1, cases 5 and 6).
In addition, a search for "partial trisomy 21" through 
Google web search engine revealed a new described PT21 
report case (Biaduń‐Popławska et al., 2014) not included in 
PubMed to be included according to matching selection cri-
teria (Table 1, case 7) detailed above.
In total, seven cases were added to the map (Table S1) 
following the new bibliographic search performed and inclu-
sion/exclusion criteria described in Materials and Methods 
section. A complete list of all retrieved included and excluded 
reports of PT21 cases is available in the Supplementary 
References file. The complete description of all these PT21 
cases is available in the Table S2, along with reasons for in-
clusion and exclusion.
3.3 | PT21 comparative map building
The updated integrated comparative map obtained as de-
scribed in the Materials and Methods section showing the 
localization of segmental anomalies of Hsa21 includes a total 
of 132 PT21 DS or non‐DS cases.
Scores for association with DS for each sequence interval 
are graphed in Figure 4. Complete data for each distinct se-
quence interval placed in the map are given in Table S1.
Analysis of the PT21 comparative map confirmed the ex-
clusion of several regions of Hsa21 as associated to DS, in 
particular 21p, 21q11, and 21q21. Highest scores were found 
in the 21q22.13 and 21q22.2 sub‐bands (Figure 4). The 34‐kb 
interval from 37,929,229 to 37,963,130 previously described 
as the minimal region associated to DS and located on distal 
21q22.13 (Pelleri et al., 2016), still has the highest scores, 
even when considering pure positively candidate scores not 
integrated with penalization/exclusion scores (Table S1). In 
addition, the duplication of this region is shared by all 92 DS 
subjects with available data about it and is absent in all 40 
non‐DS subjects with available data about it, thus confirming 
consistency with the HR‐DSCR.
A concise, sample outlook of a portion of the map is de-
picted in Figure 5a, showing in particular the three reana-
lyzed cases (Table 1, cases 1–3; #044, #046, #077 Map ID 
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here), two additionally retrieved cases (Table 1, cases 5 and 
6; #105 and #108 Map ID here), and the five newly described 
cases (Table 1, cases 4 and 7–10; #002, #127, #130, #131, 
#132 Map ID here).
4 |  DISCUSSION
Over time, the concept of a "Down syndrome critical region" 
on Hsa21 has assumed different meanings. It was mainly 
criticized observing that a certain single duplicated region is 
not responsible for all or most DS features, that is, it is not 
sufficient to cause the full DS phenotype (Korbel et al., 2009; 
Lyle et al., 2009; Papoulidis et al., 2014). From this point of 
view, modeling the genotype‐phenotype correlations using 
PT21 cases has turned into the study of distinct phenotypic 
features, in order to associate each of them to a specific re-
gion most constantly duplicated in subjects presenting with 
the feature (Korbel et al., 2009; Korenberg et al., 1994; Lyle 
et al., 2009). This approach has certainly been successful in 
suggesting that specific Hsa21 subregions of various sizes are 
mostly associated to hypotonia (Lyle et al., 2009), to acute 
megakaryoblastic leukemia and transient myeloproliferative 
disorder (Korbel et al., 2009; Pelleri et al., 2014), and to CHD 
(Pelleri et al., 2017), among others. Due to high frequency of 
an Alzheimer‐like disease in DS and the location of the APP 
(amyloid beta precursor protein) gene on Hsa21, this pheno-
type represents a particularly suggestive example of the use-
fulness of PT21 study in defining genetic determinants for a 
phenotypic feature. Recently, it has been possible to confirm 
F I G U R E  1  Array‐CGH analysis of DNA from patient MP01. Profile of chromosome 21 showing the duplication from 36,760,100 to 
46,329,175 bases present in MP01 (reanalyzed case 1). Genomic coordinates refer to the current GRCh38 human assembly
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the obligatory role of APP in the clinical, biochemical, and 
neuropathological findings of Alzheimer‐like disease study-
ing a case of PT21 with DS and without Alzheimer disease, 
lacking the APP duplication (Doran et al., 2017).
In addition to the search for genotype‐phenotype correla-
tions aimed at dissecting single phenotypes, a few features 
regularly present at the highest frequency in subjects with 
DS can be considered so that the DSCR is viewed as the re-
gion which "suffices to induce the main phenotypic symp-
toms of the classic syndrome of trisomy 21" (Rethore, 1981). 
Therefore, using the diagnosis of DS itself as the phenotype 
to be mapped, the PT21 approach should point to the "mini-
mal" Hsa21 region associated to the DS core features, notably 
ID. Actually, while any of the long list of symptoms and signs 
observed in DS may be absent in a proportion of the subjects, 
even at a high extent, ID and the typical facies are virtually 
universal, if cases with mosaicism are excluded. The genetic 
marker associated to these features should be, in principle, 
robust as the extra copy of the whole Hsa21. Dissection of 
small regions allowed by the variety of breakpoints delimit-
ing duplicated regions in subjects with PT21 has repeatedly 
pointed to 21q22 band as associated to DS. Our systematic 
reanalysis of cytogenetic maps from 125 subjects with PT21, 
integrating them under a common and updated framework, 
has suggested that the duplication of a small 34‐kb region on 
distal 21q22.13 (HR‐DSCR) is fully coherent with the diag-
nosis of DS, while the disomic state of this region is consis-
tent with a non‐DS phenotype (Pelleri et al., 2016).
F I G U R E  2  Array‐CGH analysis of DNA from patient MP03. Profile of chromosome 21 showing the duplication from 14,112,687 to 
28,015,203 bases present in MP03 (reanalyzed case 2). Genomic coordinates refer to the current GRCh38 human assembly
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In this work, we have tested if the HR‐DSCR limits could 
be refined by reanalyzing PT21 cases already included in the 
integrated map, and also if this model is prospectively consis-
tent with additional PT21 cases not described at the moment 
of building the original map.
Regarding the reanalysis, we were successful in delineating 
duplicated regions from subjects MP01 (case 1, Map ID here 
#044), MP03 (case 2, Map ID here #046), and proband case 
number 3 (Map ID here #077), whose DNA was originally 
investigated by McCormick and coll. (McCormick et al., 
1989), Petersen and coll. (Petersen et al., 1990), and Mattina 
and coll. (Mattina et al., 1997), respectively, and in this work 
has been subjected to array‐CGH. The array‐CGH analysis was 
able to clarify the breakpoints of the trisomic portions. The 
refinement of the limits in these reanalyzed cases was fully 
consistent with the previous reports and was fully consistent 
with the trisomic state of HR‐DSCR in the subject with DS 
and its disomic state in the subjects without a diagnosis of DS.
F I G U R E  3  Array‐CGH analysis of DNA from patient #077. Profile of chromosomes 9 and 21 showing the duplication of chromosome 
9 from 123,265,569 to 136,502,696 and from 137,666,340 to 138,059,636 bases and the duplication of chromosome 21 from 13,268,071 to 
32,197,958 present in case #077 (reanalyzed case 3). Genomic coordinates refer to the current GRCh38 human assembly
F I G U R E  4  Genotype–phenotype 
correlation in 132 cases of partial trisomy 
21. The X‐axis displays the score for 
association with DS for each sequence 
interval of 50 kb, shown as median of the 
values assigned to each map row (Table 
S1) that is comprised in each interval. The 
Y‐axis represents the position along Hsa21 
(scale in megabases, Mb)
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Regarding the verification of new cases, we accurately 
checked for any new reports published in the last two years 
and thus not considered in the original PT21 map. We further 
found five recent detailed descriptions (Table 1, cases 4 and 
7–10) and two previously described cases not included in the 
original PT21 map (Table 1, cases 5 and 6) fulfilling criteria 
for the inclusion on the PT21 integrated map. Each of them 
deserved a specific publication due to the extreme rarity of 
each of these cases. The stringent criteria that we have defined 
for the establishment of genotype‐phenotype correlations in 
this type of study (Pelleri et al., 2016) have been very use-
ful to guide the analysis of these new cases. Correlation of 
the clinical data to the cytogenetic map was consistent with 
the notion that all the subjects lacking the duplication of the 
HR‐DSCR were not diagnosed with DS, although these new 
cases did not allow further refinement of the region because 
the breakpoints of the duplicated portions were not within it. 
Remarkably, cases 1 and 9 (Figure 5a) alone would be suffi-
cient to exclude very large portions of Hsa21 as associated 
to the diagnosis of DS delimiting a region of about 2.8 Mb 
(36,760,100–39,605,955) in which the HR‐DSCR is located 
in the center.
Interestingly, the girl with a duplication of 2.78  Mb of 
chromosome 21q22.11 (Table 1, case 8) (Weisfeld‐Adams 
et al., 2016) was considered borderline and without a clear 
diagnosis of DS. Regarding the two most constant features, 
the typical facies and the characteristic ID, the observation of 
the girl's picture (Figure 1 in (Weisfeld‐Adams et al., 2016): 
absence of oblique eyes and of gestalt recognition of the typi-
cal DS facies assessed through blind, independent evaluation 
by the clinicians involved in this work) and the phenotypic 
description lead to the non‐DS classification of the patient. 
In addition, the author reporting the case stated that, although 
showing some grade of developmental delay, the patient 
"lacked the happy, sociable affect observed in many children 
with DS". These findings are consistent with the lack of HR‐
DSCR in this subject.
Taken together, all the findings presented here further 
support the concept that the distal part of the 21q22.13 sub‐
band is strongly associated to diagnosis of DS while other 
regions are not, and they were all consistent with the HR‐
DSCR model, although the limits of the reported duplications 
did not allow further refinement of the region or the con-
firmation of its narrowest extension. It should also be noted 
F I G U R E  5  Concise outlook (a) of a portion of the partial trisomy 21 map. Each column represents the chromosome 21 structure (in 
megabases, Mb) of partial trisomy 21 subjects with or without Down syndrome (DS or non‐DS). For each subject the case number (n.), the updated 
map identifier (ID) and the corresponding previous map ID if present (Pelleri et al., 2016) are reported. The ten cases reanalyzed or reviewed 
here are reported together with Map ID #116 and the duplication coded as structural variant nsv1060057 which delimited the proximal and distal 
highly restricted DS critical region (HR‐DSCR, red continuous line) boundaries, respectively. Red boxes, candidate or not excluded regions; green 
boxes, excluded regions; white boxes: information not available with certainty; blue boxes, monosomic regions. A zoom‐in (b) of the case (#116 
here and #113 in the previous study (Pelleri et al., 2016)) and the CNV (nsv1060057) strictly defining HR‐DSCR limits are shown here. Rows: 
Hsa21 sequence intervals (only those centered on HR‐DSCR are represented here). Red = candidate or not excluded regions; green = excluded 
regions. Levels of overlapping among intervals are indicated by increasingly darker violet color of the coordinates; blue italics indicate coordinates 
overlapping (Start or End) or nesting (Start and End) with the immediately previous interval (row). HR‐DSCR coordinates: 37,929,229–37,963,130. 
Complete map is available as Table S1
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that variability both in Hsa21 (Sailani et al., 2013) or in other 
chromosomes (Priest et al., 2012) originating from CNVs or 
SNPs also contributes to both normal and DS phenotypes 
(Antonarakis, 2017).
A relevant problem remains to be the identification and 
characterization of the genetic determinants presumably lo-
cated in the HR‐DSCR. Gene databases, as well as accurate 
transcriptome maps based on the use of known probes to ob-
tain gene expression profiling data for organs involved in DS 
phenotypes such as hippocampus (Caracausi et al., 2016) or 
heart (Caracausi, Piovesan, Vitale, & Pelleri, 2017) might be 
of limited help in the hypothesis that the genetic determinants 
are presently uncharacterized. It is still possible that, due to 
the possible extremely low size of human introns (Piovesan 
et al., 2015), one or more spliced transcripts originate from 
this small region. RNA high‐throughput sequencing (Wang, 
Gerstein, & Snyder, 2009) or ENCODE (Encyclopedia of 
DNA Elements) project (ENCODE Project Consortium, 
2012) data may offer the possibility to identify novel func-
tional elements; however, we have not had to date success in 
using them to the aim of a better characterization of the HR‐
DSCR. Other possibilities include the presence of unknown 
microRNA in the HR‐DSCR (Kozomara & Griffiths‐Jones, 
2014), as the field of non‐coding RNA involved in DS patho-
genesis has been recently explored (Karaca et al., 2017; Xu 
et al., 2013; Zhao, Jaber, Percy, & Lukiw, 2017) revealing 
the functions of several microRNA located on other Hsa21 
regions with the capability to potentially regulate over 3,600 
protein‐encoding genes (Alexandrov, Percy, & Lukiw, 2017; 
Li et al., 2012; Quinones‐Lombrana & Blanco, 2015).
While this work was in revision, an update in the Ensembl 
and UCSC genome browsers actually mapped two small new 
exons on the KCNJ6 locus (OMIM # 600877) encoding po-
tassium voltage‐gated channel subfamily J member 6, based 
on automated parsing of high throughput RNA sequencing 
(RNA‐Seq) data. Remarkably, this predicts a size extension 
for the KCNJ6 locus from 292,216 bp as currently reported 
in NCBI Gene database (coordinates 37,624,223–37,916,438 
in human genome map GRCh38.p12) to 497,787  bp 
(37,623,559–38,121,345). This transcript allows the predic-
tion of a new intron which totally encompasses HR‐DSCR 
and preliminary experimental data confirm the existence of 
this intron. Interestingly, according to RNA‐Seq Expression 
Data from GTEx as reported in the UCSC browser, this tran-
script appears to be expressed at a high level in the brain and 
in the pituitary gland, in particular in the cerebellum, hip-
pocampus, and cortex within the brain, regions well known 
for their specific alteration in DS (Stagni, Giacomini, Emili, 
Guidi, & Bartesaghi, 2018). While this update suggests the 
presence of transcribed DNA in the HR‐DSCR for the first 
time, further work will be necessary to characterize structure 
and function of this complex locus.
Moreover, the HR‐DSCR might function as a long‐range 
interactor with other chromosomes, although preliminary 
analysis of databases derived from high‐throughput chromo-
some conformation capture data (Hi‐C) (Durand et al., 2016) 
was not able to retrieve useful results (data not shown). An 
interesting possibility is to generate trisomy 21 cells with the 
selective deletion of a single copy of the HR‐DSCR to com-
pare the features of fully trisomic, HR‐DSCR deleted and 
normal cells to prove that the critical region is exerting some 
function, for example, modifying the metabolic profile that 
has recently been found to be specifically altered in DS by 
metabolome analysis (Caracausi et al., 2018). The descrip-
tion of the CRISPR/Cas9 method (Bauer, Canver, & Orkin, 
2015) may make the realization of such a sophisticated study 
model realistic (Harrison, Sanz, & Hollywood, 2016).
Therefore, while a relevant body of cytogenetic data ob-
tained from the analysis of PT21 cases strongly suggests that 
there should be some critical elements for the pathogenesis 
of DS present in the distal part of the 21q22.13 sub‐band, 
further studies are needed for additional verification of the 
limits of the region in any case of PT21 reported in the future 
as well as for the characterization of functional loci within it. 
The success of these objectives might be critical to build a 
rational foundation for a treatment of DS ID.
In conclusion, the findings presented here represent the 
most comprehensive study on PT21 and further support the 
association of the HR‐DSCR with the diagnosis of DS, rep-
resenting an unbiased validation of the original model that 
could be performed also in the future. Further studies are 
needed to identify and characterize genetic determinants pre-
sumably located in the HR‐DSCR and functionally associ-
ated to the critical manifestations of DS.
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